CA-SCIENTIST.COM
19.6.2024 13:56:28 CEST | Business Wire | Press release
Scientist.com, the world’s leading marketplace for biopharma research, today announced the launch of a new large language model (LLM)-powered research assistant called Elisa, named in homage to a widely used research assay and to ELIZA, an early 1960s chatbot. Elisa is the newest addition to a suite of proprietary AI-powered apps created by Scientist.com to improve and accelerate drug research. Marketplace users can now benefit from a powerful, scalable, and intuitive LLM assistant that understands the nuances of pharmaceutical research and has been trained on Scientist.com’s public data sources.
“Elisa is a bridge between advanced technology and our customers, providing them with instant access to marketplace information and a conversational interface that understands their research needs,” said Chris Petersen, Founder and CTO of Scientist.com. “It’s the latest in a series of LLM-powered tools we’ve built to help life science researchers run their drug discovery programs faster and at lower cost.”
Elisa addresses three key challenges for pharma and biotech companies integrating large language models into their operations:
1. It guarantees complete privacy and confidentiality of all data.
2. It provides a cost-efficient solution with the capabilities and flexibility of high-end platforms like Azure or Amazon.
3. It eliminates the need for extensive technical expertise to develop and operate a private LLM on your own infrastructure.
Other LLM-enabled tools on the Scientist.com marketplace help marketplace users negotiate pricing with suppliers, respond quickly to supplier messages, find services and products, and understand legal agreements.
The company also uses machine learning algorithms trained on nearly a decade of marketplace data to create proprietary predictive models that help researchers find and evaluate the best technology and labs for their research needs as well as forecast supplier performance once the research project is initiated. These include the Tumor Model FinderTM, which compares DNA sequencing data on 10,000 oncology models to help researchers identify and purchase the most appropriate model.
To learn more about how Scientist.com is using artificial intelligence across its platform, visit https://scientist.com/ai/ or contact marketing@scientist.com.
About Scientist.com
Scientist.com is the world’s leading AI-enabled marketplace for scientific research. The marketplace simplifies drug discovery research, saving time and money and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 100 biotechnology companies, and the US NIH.
Media contact: For additional information or to schedule an interview with Chris Petersen, please contact Sean at sean@scientist.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619993515/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named Official Foreign Exchange Provider of the ABB FIA Formula E World Championship10.3.2026 13:30:00 CET | Press release
Delivering exclusive commercial FX solutions to the world’s premier all-electric racing series Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has partnered with Formula E, the world’s first all-electric FIA World Championship and B Corp Certified sport. Under the agreement, Corpay becomes the exclusive and Official Foreign Exchange Provider of the ABB FIA Formula E World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310640540/en/ The ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation with the GEN3 Evo race continuing to set a new benchmark as the fastest-accelerating FIA single-seater, rocketing from 0-60 mph in an astonishing 1.82 seconds. Through th
Wolters Kluwer Releases 2026 Future Ready Lawyer Survey Report, Highlighting Rapid AI Gains and Shifting Power Dynamics10.3.2026 13:00:00 CET | Press release
Global survey of legal professionals reveals strong momentum behind AI investment and workflow transformation Wolters Kluwer Legal & Regulatory has published the results of its global 2026 Future Ready Lawyer Survey, the preeminent source of insights from lawyers in law firms and corporate legal departments across the U.S., China and nine European countries. The findings show an industry coming to grips with the accelerated adoption of AI technology, an ambitious undertaking that has yielded long sought-after efficiencies across workflows and business practices, while raising unexpected challenges to ethics and infrastructure. “The Future Ready Lawyer global report has always reflected an industry in motion,” said Martin O'Malley, CEO of Wolters Kluwer Legal & Regulatory. “What’s most striking this year is how rapidly legal professionals are accelerating to meet that change by reshaping business models, rethinking long‑held dynamics, and embracing new ways to deliver value through both
Armis Announces Armis Centrix™ for Vulnerability Management Detection and Response to Reduce Cyber Risk and Eliminate Operational Friction10.3.2026 13:00:00 CET | Press release
Solution empowers organizations to continuously and accurately detect vulnerabilities across the entire attack surface, while reducing scan volume and impact Armis, the cyber exposure management & security company, today announced Armis Centrix™ for Vulnerability Management Detection and Response. The solution enables security teams to precisely identify and validate vulnerabilities across all of an organization’s assets in real time. Armis’ unified approach to vulnerability assessment results in greater accuracy, faster detection time and reduced operational costs. "Waiting weeks for a vulnerability scan that still misses essential assets is no longer sufficient to combat AI-powered cyberattacks,” said Nadir Izrael, CTO and Co-Founder at Armis. “Organizations need a continuous view of their complete environment to stay ahead of threats. Armis' new solution delivers more accurate, targeted results than traditional vulnerability management solutions with a fraction of the scans. It empo
United UATP, Powered by TreviPay, Expands Corporate Travel Billing Program to New Global Markets10.3.2026 13:00:00 CET | Press release
Strategic market entry to Europe, Australia and New Zealand further strengthens United Airlines’ ability to serve agency and corporate customers with cost-free billing, flexible air travel payment options and enhanced reporting tools UATP, the global network that enables organizations to simplify payment processes and expand their payment capabilities, today announced the expansion of United Airlines’ cost-free UATP billing program (“United UATP”), powered by TreviPay, to Europe, Australia and New Zealand. This expansion opens new opportunities for corporate customers and travel agencies in these regions to access the benefits of United UATP, including cost-free, streamlined travel expense reconciliation. Since 2015, United UATP has collaborated with TreviPay, a fully managed B2B payments platform, to power its streamlined solution for air travel payments in the U.S. and Canada. For companies currently benefitting from the United UATP billing program, TreviPay handles customer service,
Nexpring Health Invests in May Health to Advance a Novel Technology to Treat PCOS-Related Infertility10.3.2026 13:00:00 CET | Press release
Strategic investment advances Nexpring Health's mission to move the fertility field forward, placing clinicians, embryologists, and fertility clinics at the center of every breakthrough, so they can focus on what matters most, their patients. Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, today announced a strategic investment in May Health, a medical device company pioneering a novel treatment approach for women with polycystic ovary syndrome (PCOS)-related infertility. Nexpring Health joined May Health’s €10 million ($11.7M) financing round alongside investors including Sofinnova Partners, Trill Impact, and Bpifrance. This investment reflects Nexpring Health's commitment to driving meaningful innovation that moves the field of fertility care forward and goes beyond the products in the lab by supporting the innovations that redefine what’s possible for patients and the clinicians who serve them. Backing the Breakthrough That PCOS Patients Need PC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom